Compare PRAA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | STTK |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | 170 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.0M | 652.4M |
| IPO Year | 2002 | 2020 |
| Metric | PRAA | STTK |
|---|---|---|
| Price | $20.27 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | 444.7K | ★ 1.5M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $1,201,837,000.00 | $1,000,000.00 |
| Revenue This Year | $8.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $1.70 |
| 52 Week High | $22.55 | $8.33 |
| Indicator | PRAA | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 43.51 |
| Support Level | $18.32 | $5.85 |
| Resistance Level | $21.39 | $7.83 |
| Average True Range (ATR) | 0.89 | 0.47 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 70.95 | 32.44 |
PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.